

  <!doctype html>
<html lang="en-US">

<!-- Mirrored from www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/ by HTTrack Website Copier/3.x [XR&CO'2014], Tue, 04 Oct 2022 17:41:10 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1">
    <link rel="profile" href="https://gmpg.org/xfn/11">
    <link rel="preload" as="font" type="font/woff2" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/fonts/InventionVF_W_Wght.woff2" crossorigin="anonymous">
<link rel="preload" as="font" type="font/woff2" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/fonts/InventionVF_Italics_W_Wght.woff2" crossorigin="anonymous">    <meta name='robots' content='index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1' />

	<!-- This site is optimized with the Yoast SEO plugin v18.2 - https://yoast.com/wordpress/plugins/seo/ -->
	<title>Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer - Merck.com</title>
	<link rel="canonical" href="https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/" />
	<meta property="og:locale" content="en_US" />
	<meta property="og:type" content="article" />
	<meta property="og:title" content="Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer - Merck.com" />
	<meta property="og:description" content="Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA) in advanced renal cell carcinoma (RCC) and head and neck cancer for the following additional indications in Japan: KEYTRUDA in combination with Inlyta (axitinib) for the first-line treatment of patients with radically unresectable or metastatic RCC; KEYTRUDA in combination with chemotherapy for the first-line treatment of patients with recurrent or distant metastatic head and neck cancer; and KEYTRUDA monotherapy for the first-line treatment of patients with recurrent or distant metastatic head and neck cancer. “Advanced renal cell carcinoma and head and neck cancer have historically been associated with poor outcomes and new treatment options are needed in Japan,” said Dr. Jonathan Cheng, vice president, oncology clinical research, Merck Research Laboratories. “Today’s" />
	<meta property="og:url" content="https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/" />
	<meta property="og:site_name" content="Merck.com" />
	<meta property="article:modified_time" content="2022-10-04T04:05:43+00:00" />
	<meta property="og:image" content="https://www.businesswire.com/images/spacer.gif" />
	<meta name="twitter:card" content="summary_large_image" />
	<meta name="twitter:label1" content="Est. reading time" />
	<meta name="twitter:data1" content="24 minutes" />
	<script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebSite","@id":"https://www.merck.com/#website","url":"https://www.merck.com/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://www.merck.com/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/#primaryimage","inLanguage":"en-US","url":"https://www.businesswire.com/images/spacer.gif","contentUrl":"https://www.businesswire.com/images/spacer.gif"},{"@type":"WebPage","@id":"https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/#webpage","url":"https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/","name":"Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer - Merck.com","isPartOf":{"@id":"https://www.merck.com/#website"},"primaryImageOfPage":{"@id":"https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/#primaryimage"},"datePublished":"2019-12-20T06:45:00+00:00","dateModified":"2022-10-04T04:05:43+00:00","breadcrumb":{"@id":"https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/"]}]},{"@type":"BreadcrumbList","@id":"https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https://www.merck.com/news-archive/"},{"@type":"ListItem","position":2,"name":"Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer"}]}]}</script>
	<!-- / Yoast SEO plugin. -->


<link rel='dns-prefetch' href='http://s.w.org/' />
<link rel='dns-prefetch' href='http://v0.wordpress.com/' />
<link rel='stylesheet' id='single-news-styles-css'  href='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/css/single-news_item.min.css?ver=20200302' media='all' />
<link rel='stylesheet' id='wp-block-library-css'  href='https://www.merck.com/wp-includes/css/dist/block-library/style.min.css?ver=5.9.4' media='all' />
<style id='wp-block-library-inline-css'>
.has-text-align-justify{text-align:justify;}
</style>
<link rel='stylesheet' id='mediaelement-css'  href='https://www.merck.com/wp-includes/js/mediaelement/mediaelementplayer-legacy.min.css?ver=4.2.16' media='all' />
<link rel='stylesheet' id='wp-mediaelement-css'  href='https://www.merck.com/wp-includes/js/mediaelement/wp-mediaelement.min.css?ver=5.9.4' media='all' />
<link rel='stylesheet' id='elasticpress-related-posts-block-css'  href='https://www.merck.com/wp-content/mu-plugins/search/elasticpress/dist/css/related-posts-block-styles.min.css?ver=3.6.5' media='all' />
<style id='global-styles-inline-css'>
body{--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--duotone--dark-grayscale: url('#wp-duotone-dark-grayscale');--wp--preset--duotone--grayscale: url('#wp-duotone-grayscale');--wp--preset--duotone--purple-yellow: url('#wp-duotone-purple-yellow');--wp--preset--duotone--blue-red: url('#wp-duotone-blue-red');--wp--preset--duotone--midnight: url('#wp-duotone-midnight');--wp--preset--duotone--magenta-yellow: url('#wp-duotone-magenta-yellow');--wp--preset--duotone--purple-green: url('#wp-duotone-purple-green');--wp--preset--duotone--blue-orange: url('#wp-duotone-blue-orange');--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}
</style>
<link rel='stylesheet' id='all-css-12' href='https://www.merck.com/wp-content/plugins/seriously-simple-podcasting/assets/css/recent-episodes.css?m=1664556542g' type='text/css' media='all' />
<link rel='stylesheet' id='qm-objectcache-style-css'  href='https://www.merck.com/wp-content/mu-plugins/qm-plugins/qm-object-cache/css/style.css?ver=0.1' media='all' />
<link rel='stylesheet' id='Mco-styles-css'  href='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/css/style.min.css?ver=20190301' media='all' />
<link rel="https://api.w.org/" href="https://www.merck.com/wp-json/" /><link rel="alternate" type="application/json" href="https://www.merck.com/wp-json/wp/v2/news_item/745810" /><link rel='shortlink' href='https://www.merck.com/?p=745810' />
<link rel="alternate" type="application/json+oembed" href="https://www.merck.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fmercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance%2F" />
<link rel="alternate" type="text/xml+oembed" href="https://www.merck.com/wp-json/oembed/1.0/embed?url=https%3A%2F%2Fwww.merck.com%2Fnews%2Fmercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance%2F&amp;format=xml" />

<link rel="alternate" type="application/rss+xml" title="Podcast RSS feed" href="https://www.merck.com/feed/podcast" />

<script type="text/javascript">
var dataLayer = dataLayer || [];
dataLayer.push({"user":{"role":"visitor","isLoggedIn":false}});
dataLayer.push({"site":[]});
dataLayer.push({"page":{"page_wpid":"745810","page_language":"en_us","page_lineofbusiness":"human health","page_accessibility":"publish","page_title":"merck\u2019s keytruda\u00ae (pembrolizumab) approved in japan for three new first-line indications across advanced renal cell carcinoma (rcc) and recurrent or distant metastatic head and neck cancer"}});
</script>
<script type="text/javascript">
(
        function( w, d, s, l, i ) {
            w[l] = w[l] || [];
            w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} );
					var f = d.getElementsByTagName( s )[0],
						j = d.createElement( s ), dl = l !== 'dataLayer' ? '&l=' + l : '';
					j.async = true;
					j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
					f.parentNode.insertBefore( j, f );
				}
        )( window, document, 'script', 'dataLayer', 'GTM-M74WZDM' );
</script>
<meta name="page_wpid" content="745810" /><meta name="page_language" content="en_US" /><meta name="page_lineofbusiness" content="Human Health" /><meta name="page_accessibility" content="publish" /><meta name="page_title" content="merck’s keytruda® (pembrolizumab) approved in japan for three new first-line indications across advanced renal cell carcinoma (rcc) and recurrent or distant metastatic head and neck cancer" />        <link rel="apple-touch-icon" sizes="180x180" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/apple-touch-icon.png">
    <link rel="icon" type="image/png" sizes="32x32" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/favicon-16x16.png">

    <link rel="manifest" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/site.webmanifest">
    <link rel="mask-icon" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/safari-pinned-tab.svg" color="#ffffff">
    <link rel="shortcut icon" href="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/favicon.ico">
    <meta name="msapplication-TileColor" content="#ffffff">
    <meta name="msapplication-config" content="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/browserconfig.xml">
    <meta name="theme-color" content="#ffffff">
    
<style>
    :root {
        --colorTextPrimary: #000000;
        --colorPrimary: #00857C;
        --colorPrimaryLight: #6ECEB2;
        --colorPrimaryDark: #005C55;
        --colorPrimaryDarkBlue: #0C2340;
        --colorSecondaryLime: #BFED33;
        --colorSecondaryLemon: #FFF063;
        --colorSecondaryPastelBlue: #69B8F7;
        --colorSecondaryVistaBlue: #688CE8;
        --colorSecondaryRichBlue: #5450E4;
        --colorBlack: #000000;
        --colorWhite: #FFFFFF;
        --colorOffWhite: #F7F7F7;
        --colorGray: #757575;
        --colorWarning: #FE0000;
        --colorSuccess: #029A01;
        --colorInfo: #1058A4;
        --colorGrayHRTwenty: #75757533;
        --colorGrayHRTen: #7575751a;
    }
</style> </head>

<body class="news_item-template-default single single-news_item postid-745810 no-sidebar">
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-M74WZDM&amp;user%5Brole%5D=visitor&amp;user%5BisLoggedIn%5D=0&amp;page%5Bpage_wpid%5D=745810&amp;page%5Bpage_language%5D=en_us&amp;page%5Bpage_lineofbusiness%5D=human%20health&amp;page%5Bpage_accessibility%5D=publish&amp;page%5Bpage_title%5D=merck%e2%80%99s%20keytruda%c2%ae%20(pembrolizumab)%20approved%20in%20japan%20for%20three%20new%20first-line%20indications%20across%20advanced%20renal%20cell%20carcinoma%20(rcc)%20and%20recurrent%20or%20distant%20metastatic%20head%20and%20neck%20cancer" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-dark-grayscale"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 0.49803921568627" /><feFuncG type="table" tableValues="0 0.49803921568627" /><feFuncB type="table" tableValues="0 0.49803921568627" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-grayscale"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 1" /><feFuncG type="table" tableValues="0 1" /><feFuncB type="table" tableValues="0 1" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-purple-yellow"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.54901960784314 0.98823529411765" /><feFuncG type="table" tableValues="0 1" /><feFuncB type="table" tableValues="0.71764705882353 0.25490196078431" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-blue-red"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 1" /><feFuncG type="table" tableValues="0 0.27843137254902" /><feFuncB type="table" tableValues="0.5921568627451 0.27843137254902" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-midnight"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0 0" /><feFuncG type="table" tableValues="0 0.64705882352941" /><feFuncB type="table" tableValues="0 1" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-magenta-yellow"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.78039215686275 1" /><feFuncG type="table" tableValues="0 0.94901960784314" /><feFuncB type="table" tableValues="0.35294117647059 0.47058823529412" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-purple-green"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.65098039215686 0.40392156862745" /><feFuncG type="table" tableValues="0 1" /><feFuncB type="table" tableValues="0.44705882352941 0.4" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 0 0" width="0" height="0" focusable="false" role="none" style="visibility: hidden; position: absolute; left: -9999px; overflow: hidden;" ><defs><filter id="wp-duotone-blue-orange"><feColorMatrix color-interpolation-filters="sRGB" type="matrix" values=" .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 .299 .587 .114 0 0 " /><feComponentTransfer color-interpolation-filters="sRGB" ><feFuncR type="table" tableValues="0.098039215686275 1" /><feFuncG type="table" tableValues="0 0.66274509803922" /><feFuncB type="table" tableValues="0.84705882352941 0.41960784313725" /><feFuncA type="table" tableValues="1 1" /></feComponentTransfer><feComposite in2="SourceGraphic" operator="in" /></filter></defs></svg><div id="page" class="site">
    <a class="skip-link screen-reader-text" href="#content">Skip to content</a>

    

    <header id="masthead" class="site-header">
                <nav id="site-navigation" class="main-navigation">
            <div class="wrapper header-wrapper">
                <div class="site-branding">
            <p class="site-title">
                <a href="https://www.merck.com/" rel="home" title="Merck.com">
            <img class="site-logo" src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/logo.jpeg" alt="Site logo" />
            </a>
            </p>
    </div><!-- .site-branding -->                <div id="mastheadMenu">
    <button id="siteSearchToggle" class="btn" aria-controls="primary-search" aria-expanded="false">
        <span class="menu-toggle-text-open">
            <img src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/search-white.svg" alt="menu icon" />
            <span>Search everything</span>
        </span>
        <span class="menu-toggle-text-close">
            <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/close.svg" alt="close icon" />Close        </span>
    </button>
    <button id="siteNavigationToggle" class="btn menu-toggle" aria-controls="primary-menu" aria-expanded="false">
        <span class="menu-toggle-text-open">
            <img src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/burger-white.svg" alt="menu icon" />Menu        </span>
        <span class="menu-toggle-text-close">
            <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/close.svg" alt="close icon" />Close        </span>
    </button>
</div>            </div><!-- .header-wrapper -->
        </nav><!-- #site-navigation -->
        <nav id="site-menu" class="main-menu">
	<div class="wrapper">
		<a class="menucrumb" href="#">Main menu</a>
		<div class="menu-main-menu-container"><ul id="menuMain" class="menu-main level-0 menu-open"><li id="menu-item-666469" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666469"><a href="https://www.merck.com/company-overview/">Company</a>
<ul class="level-1">
	<li id="menu-item-666471" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666471"><a href="https://www.merck.com/company-overview/">Company overview</a></li>
	<li id="menu-item-667007" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-667007"><a href="https://www.merck.com/stories/">Stories</a></li>
	<li id="menu-item-2773656" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2773656"><a href="https://www.merck.com/company-overview/history/">History</a></li>
	<li id="menu-item-666473" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666473"><a href="https://www.merck.com/company-overview/esg/">Environmental, Social &#038; Governance (ESG)</a>
	<ul class="level-2">
		<li id="menu-item-2388650" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2388650"><a href="https://www.merck.com/company-overview/esg/">ESG overview</a></li>
		<li id="menu-item-2388653" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2388653"><a href="https://www.merck.com/company-overview/esg/philanthropy/">Philanthropy</a></li>
		<li id="menu-item-2796573" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2796573"><a href="https://www.merck.com/company-overview/esg/merck-medical-outreach-program/">Merck Medical Outreach Program</a></li>
		<li id="menu-item-2798027" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2798027"><a href="https://www.merck.com/company-overview/esg/impact-investing/">Impact investing</a></li>
		<li id="menu-item-2804132" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2804132"><a href="https://www.merck.com/company-overview/esg/transparency-disclosures/">Transparency disclosures</a></li>
		<li id="menu-item-2808199" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2808199"><a href="https://www.merck.com/company-overview/esg/esg-resources/">ESG resources</a></li>
	</ul>
</li>
	<li id="menu-item-666474" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666474"><a href="https://www.merck.com/company-overview/leadership/">Leadership</a>
	<ul class="level-2">
		<li id="menu-item-666483" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666483"><a href="https://www.merck.com/company-overview/leadership/">Leadership overview</a></li>
		<li id="menu-item-666484" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666484"><a href="https://www.merck.com/company-overview/leadership/board-of-directors/">Board of directors</a></li>
		<li id="menu-item-666485" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666485"><a href="https://www.merck.com/company-overview/leadership/executive-team/">Executive team</a></li>
	</ul>
</li>
	<li id="menu-item-666475" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666475"><a href="https://www.merck.com/company-overview/culture-and-values/">Culture &amp; values</a>
	<ul class="level-2">
		<li id="menu-item-666488" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666488"><a href="https://www.merck.com/company-overview/culture-and-values/">Culture &#038; values overview</a></li>
		<li id="menu-item-666489" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666489"><a href="https://www.merck.com/company-overview/culture-and-values/code-of-conduct/">Code of conduct &amp; compliance</a></li>
	</ul>
</li>
	<li id="menu-item-666476" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666476"><a href="https://www.merck.com/company-overview/diversity-and-inclusion/">Diversity &amp; inclusion</a></li>
	<li id="menu-item-666477" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666477"><a href="https://www.merck.com/company-overview/policies-and-positions/">Policies &amp; positions</a></li>
	<li id="menu-item-666478" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666478"><a href="https://www.merck.com/company-overview/business-development-licensing/">Business development &amp; licensing</a></li>
	<li id="menu-item-666479" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666479"><a href="https://www.merck.com/company-overview/suppliers/">Suppliers</a>
	<ul class="level-2">
		<li id="menu-item-667793" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-667793"><a href="https://www.merck.com/company-overview/suppliers/">Suppliers overview</a></li>
		<li id="menu-item-667792" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-667792"><a target="_blank" rel="noopener" href="https://msd.quantumsds.com/">Supplier registration</a></li>
		<li id="menu-item-3601080" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3601080"><a href="https://suppliers.msd.com/">Supplier help for Ariba</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-14540" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-14540"><a href="https://www.merck.com/research/">Research</a>
<ul class="level-1">
	<li id="menu-item-666505" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666505"><a href="https://www.merck.com/research/">Research overview</a></li>
	<li id="menu-item-2388262" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-2388262"><a href="https://www.merck.com/research/covid-19/">Our COVID-19 efforts</a></li>
	<li id="menu-item-666527" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-666527"><a target="_blank" rel="noopener" href="#">Areas of focus</a>
	<ul class="level-2">
		<li id="menu-item-666509" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666509"><a href="https://www.merck.com/research/oncology/">Oncology</a></li>
		<li id="menu-item-666507" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666507"><a href="https://www.merck.com/research/vaccines/">Vaccines</a></li>
		<li id="menu-item-666508" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666508"><a href="https://www.merck.com/research/infectious-diseases/">Infectious diseases</a></li>
		<li id="menu-item-666510" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666510"><a href="https://www.merck.com/research/cardio-metabolic-disorders/">Cardio-metabolic disorders</a></li>
	</ul>
</li>
	<li id="menu-item-666511" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666511"><a href="https://www.merck.com/research/product-pipeline/">Pipeline</a></li>
	<li id="menu-item-666512" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666512"><a href="https://www.merck.com/research/discovery-development/">Discovery &amp; development</a></li>
	<li id="menu-item-3600289" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3600289"><a href="https://www.merck.com/research/rd-locations/">R&#038;D locations</a></li>
	<li id="menu-item-666513" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-666513"><a href="https://www.merck.com/research/clinical-trials/">Clinical trials</a>
	<ul class="level-2">
		<li id="menu-item-666673" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666673"><a href="https://www.merck.com/research/clinical-trials/">Clinical trials overview</a></li>
		<li id="menu-item-666672" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-666672"><a target="_blank" rel="noopener" href="https://www.merckclinicaltrials.com/">Find a trial</a></li>
		<li id="menu-item-2805336" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2805336"><a href="https://www.merck.com/research/diversity-in-clinical-trials/">Diversity in clinical trials</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-3600254" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3600254"><a href="https://www.merck.com/products/">Products</a>
<ul class="level-1">
	<li id="menu-item-666506" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666506"><a href="https://www.merck.com/products/">Products list</a></li>
	<li id="menu-item-666515" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666515"><a href="https://www.merck.com/products/patent/">Product patents</a></li>
	<li id="menu-item-14541" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-14541"><a href="https://www.merck.com/products/distributors/">Merck authorized distributors</a></li>
</ul>
</li>
<li id="menu-item-628574" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-628574"><a href="https://www.merck.com/patients/">Patients</a>
<ul class="level-1">
	<li id="menu-item-2784133" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2784133"><a href="https://www.merck.com/patients/">Patients overview</a></li>
	<li id="menu-item-2181846" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2181846"><a href="https://www.merck.com/patients/patient-financial-assistance/">Patient support programs</a></li>
	<li id="menu-item-628576" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-628576"><a href="https://www.merck.com/patients/patient-resources/">Patient resources</a></li>
	<li id="menu-item-628575" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-628575"><a href="https://www.merck.com/patients/patient-and-treatment-education/">Patient &amp; treatment education</a></li>
</ul>
</li>
<li id="menu-item-666493" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-666493"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en">Careers</a>
<ul class="level-1">
	<li id="menu-item-696146" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696146"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/home">Careers</a></li>
	<li id="menu-item-696145" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696145"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/search-results">Search jobs</a></li>
	<li id="menu-item-696144" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-696144"><a href="#">Our divisions</a>
	<ul class="level-2">
		<li id="menu-item-696175" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696175"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/research-laboratories">Research &#038; development</a></li>
		<li id="menu-item-696174" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696174"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/manufacturing">Manufacturing &#038; supply</a></li>
		<li id="menu-item-696172" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696172"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/human-health">Human Health</a></li>
		<li id="menu-item-696171" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696171"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/animal-health">Animal Health</a></li>
		<li id="menu-item-696164" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696164"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/global-support-functions">Global support functions</a></li>
	</ul>
</li>
	<li id="menu-item-696141" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696141"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/veteran-opportunities">Veterans</a></li>
	<li id="menu-item-696140" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696140"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/student-opportunities">Student opportunities</a></li>
	<li id="menu-item-696139" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696139"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/compensation-and-benefits">Compensation &#038; benefits</a></li>
	<li id="menu-item-696138" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696138"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/hiring-process">How we hire</a></li>
	<li id="menu-item-696137" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696137"><a target="_blank" rel="noopener" href="https://jobs.msd.com/gb/en/home">MSD Careers</a></li>
	<li id="menu-item-696136" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696136"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/events">Events</a></li>
	<li id="menu-item-696134" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-696134"><a target="_blank" rel="noopener" href="https://jobs.merck.com/us/en/jointalentcommunity?applyType=JTC">Talent community</a></li>
</ul>
</li>
<li id="menu-item-137022" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-137022"><a href="https://www.merck.com/investor-relations/">Investors</a>
<ul class="level-1">
	<li id="menu-item-223087" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-223087"><a href="https://www.merck.com/investor-relations/">Investors overview</a></li>
	<li id="menu-item-220674" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-220674"><a href="https://www.merck.com/investor-relations/events-and-presentations/">Events &amp; presentations</a></li>
	<li id="menu-item-220673" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-220673"><a href="https://www.merck.com/investor-relations/financial-information/">Financial information</a>
	<ul class="level-2">
		<li id="menu-item-666494" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666494"><a href="https://www.merck.com/investor-relations/financial-information/">Financial information overview</a></li>
		<li id="menu-item-666495" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666495"><a href="https://www.merck.com/investor-relations/financial-information/sec-filings/">SEC filings</a></li>
	</ul>
</li>
	<li id="menu-item-220672" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-220672"><a href="https://www.merck.com/investor-relations/stock-info/">Stock information</a></li>
	<li id="menu-item-220671" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-220671"><a href="https://www.merck.com/investor-relations/investor-resources/">Investor resources</a>
	<ul class="level-2">
		<li id="menu-item-666496" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666496"><a href="https://www.merck.com/investor-relations/investor-resources/">Investor resources overview</a></li>
		<li id="menu-item-2793045" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2793045"><a href="https://www.merck.com/investor-relations/organon-resources/">Organon resources</a></li>
		<li id="menu-item-666497" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-666497"><a href="https://www.merck.com/investor-relations/investor-resources/information-request/">Request for information</a></li>
	</ul>
</li>
</ul>
</li>
<li id="menu-item-650872" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-650872"><a href="https://www.merck.com/media/">Media</a>
<ul class="level-1">
	<li id="menu-item-650874" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650874"><a href="https://www.merck.com/media/">Media overview</a></li>
	<li id="menu-item-650878" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650878"><a href="https://www.merck.com/media/news/">News releases</a></li>
	<li id="menu-item-650884" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650884"><a href="https://www.merck.com/media/company-statements/">Company statements</a></li>
	<li id="menu-item-3544562" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3544562"><a href="https://www.merck.com/media/media-library/">Media library &amp; contacts</a>
	<ul class="level-2">
		<li id="menu-item-3544537" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3544537"><a href="https://www.merck.com/media/media-library/">Media contact &#038; library overview</a></li>
		<li id="menu-item-650879" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-650879"><a href="https://www.merck.com/media/media-library/company-fact-sheet/">Company fact sheet</a></li>
	</ul>
</li>
</ul>
</li>
</ul></div>		<div class="side-section">
															<div class="image">
						<picture>
							<source media="(max-width: 1279px)"
								data-srcset="https://www.merck.com/wp-content/uploads/sites/5/2021/11/covid-19-response-hero.jpg?resize=370,418">
							<source media="(min-width: 1280px)"
								data-srcset="https://www.merck.com/wp-content/uploads/sites/5/2021/11/covid-19-response-hero.jpg?resize=486,432">
							<img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/uploads/sites/5/2021/11/covid-19-response-hero.jpg?resize=486,432" alt="two scientists wearing masks">
						</picture>
					</div>
													<div class="tagline"></div>
													<h4>Our COVID-19 efforts</h4>
													<a class="btn" href="https://www.merck.com/research/covid-19/" title="Learn more" target="">Learn more</a>
									</div>
		<div class="bottom-section">
			<a class="btn" href="https://www.merck.com/contact-us/">Contact us</a>
			<p>
				<a href="https://www.msd.com/contact-us/worldwide-locations/" target="_blank" rel="noopener">Worldwide</a>
				<small>Countries outside of the United States and Canada.</small>
			</p>
		</div>
	</div>
</nav><!-- #site-menu -->

        <form id="site-search" role="search" method="get" class="search-form" action="https://www.merck.com/" autocomplete="off">
    <h1>What can we help you find?</h1>
    <div id="site-search-box" class="input-box autocomplete">
        <span class="screen-reader-text">Search for:</span>
        <input type="text" class="search-field autocomplete-input" placeholder="Search here …" value="" name="s" aria-label="Search site">
        <button type="submit" class="submit search-submit"></button>
    </div>
    <div id="search_suggestion_result"></div> 
    </form>


<script>
    theme_directory = "https://www.merck.com/wp-content/themes/mhh-merck-mco-theme";  
</script>
    </header><!-- #masthead -->
    <div id="content" class="site-content">


	<div id="primary" class="content-area">
                    <div class="breadcrumbs wrapper text-descriptive">
                <span>
                    <span>
                        <a href="https://www.merck.com/media/">
                            Media
                        </a> &gt; 
                        <span>
                            <a href="https://www.merck.com/media/news/">
                                News releases
                            </a> &gt; 
                            <span class="breadcrumb_last" aria-current="page">
                                News release
                            </span>
                        </span>
                    </span>
                </span>
            </div>
        		<main id="main" class="site-main single-news_item">
            <article id="post-745810" class="post-745810 news_item type-news_item status-publish hentry tag-corporate-news tag-latest-news tag-oncology tag-oncology-newsroom tag-prescription-medicine-news tag-press-release">

                <div class="entry-content">
                    <div class="news-itm-header-container wrapper">
                        <div>
                            <h2 class="entry-title">
                                Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer                            </h2>
                        </div>
                    </div>

                    <div class="wrapper">
                        <div class="entry-header-links-div">
                                                        <a id="btnSave2PDF" href="https://s2.q4cdn.com/584635680/files/doc_news/Mercks-KEYTRUDA-pembrolizumab-Approved-in-Japan-for-Three-New-First-Line-Indications-Across-Advanced-Renal-Cell-Carcinoma-RCC-and-Rec-MGOVI.pdf" target="_blank"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 16 16">
    <path fill="#00857C" d="M2.556 3.894v9.326h10.888V3.894H15v9.326c0 .863-.7 1.555-1.556 1.555H2.556A1.555 1.555 0 0 1 1 13.22V3.894h1.556zM8.924.775v8.59L10.9 7.391l1.1 1.1-3.85 3.85-3.85-3.85 1.1-1.1 1.974 1.974V.775h1.551z" />
</svg>
 Save</a>
                                                        </div>
                        
                        <div class="news-item-text-container">
                            <p class="date-text">
                                December 20, 2019 6:45 am ET                            </p>
                            <p class="bwalignc"> KEYTRUDA Now Approved for Six Cancer Types Plus Microsatellite Instability-High (MSI-H) Tumors in Japan </p>
<p>KENILWORTH, N.J.&#8211;(<a target="_blank" href="http://www.businesswire.com/" rel="noopener">BUSINESS WIRE</a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA) in advanced renal cell carcinoma (RCC) and head and neck cancer for the following additional indications in Japan:
</p>
<ul class="bwlistdisc">
<li>
KEYTRUDA in combination with Inlyta (axitinib) for the first-line treatment of patients with radically unresectable or metastatic RCC;
</li>
<li>
KEYTRUDA in combination with chemotherapy for the first-line treatment of patients with recurrent or distant metastatic head and neck cancer; and
</li>
<li>
KEYTRUDA monotherapy for the first-line treatment of patients with recurrent or distant metastatic head and neck cancer.
</li>
</ul>
<p>
“Advanced renal cell carcinoma and head and neck cancer have historically been associated with poor outcomes and new treatment options are needed in Japan,” said Dr. Jonathan Cheng, vice president, oncology clinical research, Merck Research Laboratories. “Today’s approval of three new first-line KEYTRUDA regimens represents a significant milestone for patients diagnosed with these aggressive forms of cancer and will provide patients in Japan with important alternatives to standard therapies.”
</p>
<p>
The approval for KEYTRUDA in combination with axitinib for radically unresectable or metastatic RCC is based on results from the KEYNOTE-426 trial, in which KEYTRUDA in combination with axitinib demonstrated statistically significant improvements in the dual primary endpoints of overall survival (OS) (HR=0.53 [95% CI, 0.38-0.74]; p=0.00005) and progression-free survival (PFS) (HR=0.69 [95% CI, 0.56-0.84]; p=0.00012) compared to sunitinib monotherapy.
</p>
<p>
The approval for KEYTRUDA for the first-line treatment of patients with recurrent or distant metastatic head and neck cancer is based on results from the Phase 3 KEYNOTE-048 trial which evaluated KEYTRUDA in combination with platinum and 5-fluorouracil (5-FU), or KEYTRUDA monotherapy compared with standard treatment (cetuximab in combination with platinum and 5-FU), as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma. In the trial, KEYTRUDA in combination with platinum and 5-FU significantly prolonged OS (HR=0.77 [95% CI, 0.63-0.93]; p=0.00335) compared with standard treatment. As monotherapy, KEYTRUDA demonstrated non-inferiority (HR=0.85 [95% CI, 0.71-1.03]; p=0.00014) compared with standard treatment. Additionally, KEYTRUDA monotherapy demonstrated a statistically significant improvement in OS in patients whose tumors expressed PD-L1 (CPS ≥1) compared with standard treatment.
</p>
<p>
“Last year, an estimated 850,000 new cancer diagnoses were made in Japan alone, underscoring the critical need for innovative research and development to identify additional treatment options,” said Jannie Oosthuizen, managing director of MSD in Japan. “The new approvals of KEYTRUDA in advanced renal cell carcinoma and head and neck cancer build on previous approvals in melanoma, advanced non-small cell lung cancer and advanced MSI-H cancers, allowing us to bring KEYTRUDA to even more patients in Japan.”
</p>
<p>
Renal cell carcinoma is by far the most common type of kidney cancer, with approximately 403,000 cases of kidney cancer diagnosed worldwide in 2018 and about 175,000 deaths from the disease. In Japan, it is estimated there were more than 24,000 people diagnosed with kidney cancer, and more than 8,000 deaths occurred in 2018.
</p>
<p>
Head and neck cancer describes a number of different tumors that develop in or around the throat, larynx, nose, sinuses and mouth. It is estimated that there were more than 705,000 new cases of head and neck cancer diagnosed and over 358,000 deaths from the disease worldwide in 2018. In Japan, it is estimated that more than 22,000 new cases of head and neck cancer were diagnosed, and more than 8,000 deaths occurred in 2018.
</p>
<p>
<b>About KEYTRUDA<sup>®</sup> (pembrolizumab) Injection </b>
</p>
<p>
KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
</p>
<p>
Merck has the industry’s largest immuno-oncology clinical research program. There are currently more than 1,000 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient’s likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.
</p>
<p>
<b>Selected Indications for KEYTRUDA<sup>®</sup> (pembrolizumab) in the U.S. </b>
</p>
<p>
<i>Melanoma </i>
</p>
<p>
KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
</p>
<p>
KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
</p>
<p>
<i>Non-Small Cell Lung Cancer</i>
</p>
<p>
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
</p>
<p>
KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
</p>
<p>
KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.
</p>
<p>
KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
</p>
<p>
<i>Small Cell Lung Cancer </i>
</p>
<p>
KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
</p>
<p>
<i>Head and Neck Squamous Cell Cancer</i>
</p>
<p>
KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).
</p>
<p>
KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [combined positive score (CPS) ≥1] as determined by an FDA-approved test.
</p>
<p>
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.
</p>
<p>
<i>Classical Hodgkin Lymphoma</i>
</p>
<p>
KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
</p>
<p>
<i>Primary Mediastinal Large B-Cell Lymphoma</i>
</p>
<p>
KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.
</p>
<p>
<i>Urothelial Carcinoma</i>
</p>
<p>
KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [combined positive score (CPS) ≥10] as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
</p>
<p>
KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
</p>
<p>
<i>Microsatellite Instability-High (MSI-H) Cancer</i>
</p>
<p>
KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)
</p>
<ul class="bwlistdisc">
<li>
solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or
</li>
<li>
colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan.
</li>
</ul>
<p>
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.
</p>
<p>
<i>Gastric Cancer</i>
</p>
<p>
KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
</p>
<p>
<i>Esophageal Cancer</i>
</p>
<p>
KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.
</p>
<p>
<i>Cervical Cancer</i>
</p>
<p>
KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
</p>
<p>
<i>Hepatocellular Carcinoma</i>
</p>
<p>
KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
</p>
<p>
<i>Merkel Cell Carcinoma</i>
</p>
<p>
KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
</p>
<p>
<i>Renal Cell Carcinoma</i>
</p>
<p>
KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
</p>
<p>
<b>Selected Important Safety Information for KEYTRUDA </b>
</p>
<p>
<b>Immune-Mediated Pneumonitis </b>
</p>
<p>
KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases. Pneumonitis occurred in 3.4% (94/2799) of patients with various cancers receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%). Pneumonitis occurred in 8.2% (65/790) of NSCLC patients receiving KEYTRUDA as a single agent, including Grades 3-4 in 3.2% of patients, and occurred more frequently in patients with a history of prior thoracic radiation (17%) compared to those without (7.7%). Pneumonitis occurred in 6% (18/300) of HNSCC patients receiving KEYTRUDA as a single agent, including Grades 3-5 in 1.6% of patients, and occurred in 5.4% (15/276) of patients receiving KEYTRUDA in combination with platinum and FU as first-line therapy for advanced disease, including Grades 3-5 in 1.5% of patients.
</p>
<p>
Monitor patients for signs and symptoms of pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.
</p>
<p>
<b>Immune-Mediated Colitis</b>
</p>
<p>
KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3 (1.1%), and 4 (&lt;0.1%). Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for Grade 4 colitis.
</p>
<p>
<b>Immune-Mediated Hepatitis (KEYTRUDA) and Hepatotoxicity (KEYTRUDA in Combination With Axitinib)</b>
</p>
<p>
<i>Immune-Mediated Hepatitis</i>
</p>
<p>
KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.4%), and 4 (&lt;0.1%). Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.
</p>
<p>
<i>Hepatotoxicity in Combination With Axitinib</i>
</p>
<p>
KEYTRUDA in combination with axitinib can cause hepatic toxicity with higher than expected frequencies of Grades 3 and 4 ALT and AST elevations compared to KEYTRUDA alone. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased ALT (20%) and increased AST (13%) were seen. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed.
</p>
<p>
<b>Immune-Mediated Endocrinopathies</b>
</p>
<p>
KEYTRUDA can cause hypophysitis, thyroid disorders, and type 1 diabetes mellitus. Hypophysitis occurred in 0.6% (17/2799) of patients, including Grade 2 (0.2%), 3 (0.3%), and 4 (&lt;0.1%). Hypothyroidism occurred in 8.5% (237/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC (16%) receiving KEYTRUDA, as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. Hyperthyroidism occurred in 3.4% (96/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%), and thyroiditis occurred in 0.6% (16/2799) of patients, including Grade 2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 0.2% (6/2799) of patients.
</p>
<p>
Monitor patients for signs and symptoms of hypophysitis (including hypopituitarism and adrenal insufficiency), thyroid function (prior to and periodically during treatment), and hyperglycemia. For hypophysitis, administer corticosteroids and hormone replacement as clinically indicated. Withhold KEYTRUDA for Grade 2 and withhold or discontinue for Grade 3 or 4 hypophysitis. Administer hormone replacement for hypothyroidism and manage hyperthyroidism with thionamides and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and withhold KEYTRUDA and administer antihyperglycemics in patients with severe hyperglycemia.
</p>
<p>
<b>Immune-Mediated Nephritis and Renal Dysfunction</b>
</p>
<p>
KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.1%), and 4 (&lt;0.1%) nephritis. Nephritis occurred in 1.7% (7/405) of patients receiving KEYTRUDA in combination with pemetrexed and platinum chemotherapy. Monitor patients for changes in renal function. Administer corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently discontinue for Grade 3 or 4 nephritis.
</p>
<p>
<b>Immune-Mediated Skin Reactions</b>
</p>
<p>
Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative dermatitis, and bullous pemphigoid, can occur. Monitor patients for suspected severe skin reactions and based on the severity of the adverse reaction, withhold or permanently discontinue KEYTRUDA and administer corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA and refer the patient for specialized care for assessment and treatment. If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.
</p>
<p>
<b>Other Immune-Mediated Adverse Reactions</b>
</p>
<p>
Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue in patients receiving KEYTRUDA and may also occur after discontinuation of treatment. For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA and administer corticosteroids. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Based on limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered. Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less following corticosteroid taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction.
</p>
<p>
The following clinically significant immune-mediated adverse reactions occurred in less than 1% (unless otherwise indicated) of 2799 patients: arthritis (1.5%), uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and encephalitis. In addition, myelitis and myocarditis were reported in other clinical trials, including classical Hodgkin lymphoma, and postmarketing use.
</p>
<p>
Treatment with KEYTRUDA may increase the risk of rejection in solid organ transplant recipients. Consider the benefit of treatment vs the risk of possible organ rejection in these patients.
</p>
<p>
<b>Infusion-Related Reactions</b>
</p>
<p>
KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% (6/2799) of patients. Monitor patients for signs and symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop infusion and permanently discontinue KEYTRUDA.
</p>
<p>
<b>Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</b>
</p>
<p>
Immune-mediated complications, including fatal events, occurred in patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of 23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6 (26%) developed graft-versus-host disease (GVHD) (1 fatal case) and 2 (9%) developed severe hepatic veno-occlusive disease (VOD) after reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute GVHD after allogeneic HSCT have also been reported in patients with lymphoma who received a PD-1 receptor–blocking antibody before transplantation. Follow patients closely for early evidence of transplant-related complications such as hyperacute graft-versus-host disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease (VOD), and other immune-mediated adverse reactions.
</p>
<p>
In patients with a history of allogeneic HSCT, acute GVHD (including fatal GVHD) has been reported after treatment with KEYTRUDA. Patients who experienced GVHD after their transplant procedure may be at increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA vs the risk of GVHD in these patients.
</p>
<p>
<b>Increased Mortality in Patients With Multiple Myeloma</b>
</p>
<p>
In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with a PD-1 or PD-L1 blocking antibody in this combination is not recommended outside of controlled trials.
</p>
<p>
<b>Embryofetal Toxicity</b>
</p>
<p>
Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.
</p>
<p>
<b>Adverse Reactions</b>
</p>
<p>
In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9% of 555 patients with advanced melanoma; adverse reactions leading to permanent discontinuation in more than one patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). The most common adverse reactions (≥20%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and nausea (21%).
</p>
<p>
In KEYNOTE-002, KEYTRUDA was permanently discontinued due to adverse reactions in 12% of 357 patients with advanced melanoma; the most common (≥1%) were general physical health deterioration (1%), asthenia (1%), dyspnea (1%), pneumonitis (1%), and generalized edema (1%). The most common adverse reactions were fatigue (43%), pruritus (28%), rash (24%), constipation (22%), nausea (22%), diarrhea (20%), and decreased appetite (20%).
</p>
<p>
In KEYNOTE-054, KEYTRUDA was permanently discontinued due to adverse reactions in 14% of 509 patients; the most common (≥1%) were pneumonitis (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions occurred in 25% of patients receiving KEYTRUDA. The most common adverse reaction (≥20%) with KEYTRUDA was diarrhea (28%).
</p>
<p>
In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 20% of 405 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most common adverse reactions (≥20%) with KEYTRUDA were nausea (56%), fatigue (56%), constipation (35%), diarrhea (31%), decreased appetite (28%), rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia (20%).
</p>
<p>
In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and either paclitaxel or paclitaxel protein-bound in metastatic squamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 15% of 101 patients. The most frequent serious adverse reactions reported in at least 2% of patients were febrile neutropenia, pneumonia, and urinary tract infection. Adverse reactions observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the exception that increased incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs 25%) were observed in the KEYTRUDA and chemotherapy arm compared to the placebo and chemotherapy arm in KEYNOTE-407.
</p>
<p>
In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in 19% of 636 patients; the most common were pneumonitis (3%), death due to unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia (7%), pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural effusion (2.2%). The most common adverse reaction (≥20%) was fatigue (25%).
</p>
<p>
In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of 682 patients with metastatic NSCLC; the most common was pneumonitis (1.8%). The most common adverse reactions (≥20%) were decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).
</p>
<p>
Adverse reactions occurring in patients with SCLC were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.
</p>
<p>
In KEYNOTE-048, KEYTRUDA monotherapy was discontinued due to adverse events in 12% of 300 patients with HNSCC; the most common adverse reactions leading to permanent discontinuation were sepsis (1.7%) and pneumonia (1.3%). The most common adverse reactions (≥20%) were fatigue (33%), constipation (20%), and rash (20%).
</p>
<p>
In KEYNOTE-048, when KEYTRUDA was administered in combination with platinum (cisplatin or carboplatin) and FU chemotherapy, KEYTRUDA was discontinued due to adverse reactions in 16% of 276 patients with HNSCC. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonia (2.5%), pneumonitis (1.8%), and septic shock (1.4%). The most common adverse reactions (≥20%) were nausea (51%), fatigue (49%), constipation (37%), vomiting (32%), mucosal inflammation (31%), diarrhea (29%), decreased appetite (29%), stomatitis (26%), and cough (22%).
</p>
<p>
In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in 17% of 192 patients with HNSCC. Serious adverse reactions occurred in 45% of patients. The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia, dyspnea, confusional state, vomiting, pleural effusion, and respiratory failure. The most common adverse reactions (≥20%) were fatigue, decreased appetite, and dyspnea. Adverse reactions occurring in patients with HNSCC were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception of increased incidences of facial edema and new or worsening hypothyroidism.
</p>
<p>
In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5% of 210 patients with cHL. Serious adverse reactions occurred in 16% of patients; those ≥1% included pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and herpes zoster. Two patients died from causes other than disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1 from septic shock. The most common adverse reactions (≥20%) were fatigue (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea (20%), and rash (20%).
</p>
<p>
In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8% of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of patients and included arrhythmia (4%), cardiac tamponade (2%), myocardial infarction (2%), pericardial effusion (2%), and pericarditis (2%). Six (11%) patients died within 30 days of start of treatment. The most common adverse reactions (≥20%) were musculoskeletal pain (30%), upper respiratory tract infection and pyrexia (28% each), cough (26%), fatigue (23%), and dyspnea (21%).
</p>
<p>
In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in 11% of 370 patients with locally advanced or metastatic urothelial carcinoma. Serious adverse reactions occurred in 42% of patients; those ≥2% were urinary tract infection, hematuria, acute kidney injury, pneumonia, and urosepsis. The most common adverse reactions (≥20%) were fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%), constipation (21%), rash (21%), and diarrhea (20%).
</p>
<p>
In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8% of 266 patients with locally advanced or metastatic urothelial carcinoma. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated patients; those ≥2% were urinary tract infection, pneumonia, anemia, and pneumonitis. The most common adverse reactions (≥20%) in patients who received KEYTRUDA were fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased appetite (21%), nausea (21%), and rash (20%).
</p>
<p>
Adverse reactions occurring in patients with gastric cancer were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.
</p>
<p>
Adverse reactions occurring in patients with esophageal cancer were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.
</p>
<p>
In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8% of 98 patients with recurrent or metastatic cervical cancer. Serious adverse reactions occurred in 39% of patients receiving KEYTRUDA; the most frequent included anemia (7%), fistula, hemorrhage, and infections [except urinary tract infections] (4.1% each). The most common adverse reactions (≥20%) were fatigue (43%), musculoskeletal pain (27%), diarrhea (23%), pain and abdominal pain (22% each), and decreased appetite (21%).
</p>
<p>
Adverse reactions occurring in patients with hepatocellular carcinoma (HCC) were generally similar to those in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception of increased incidences of ascites (8% Grades 3–4) and immune-mediated hepatitis (2.9%). Laboratory abnormalities (Grades 3–4) that occurred at a higher incidence were elevated AST (20%), ALT (9%), and hyperbilirubinemia (10%).
</p>
<p>
Among the 50 patients with MCC enrolled in study KEYNOTE-017, adverse reactions occurring in patients with MCC were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy. Laboratory abnormalities (Grades 3–4) that occurred at a higher incidence were elevated AST (11%) and hyperglycemia (19%).
</p>
<p>
In KEYNOTE-426, when KEYTRUDA was administered in combination with axitinib, fatal adverse reactions occurred in 3.3% of 429 patients. Serious adverse reactions occurred in 40% of patients, the most frequent (≥1%) were hepatotoxicity (7%), diarrhea (4.2%), acute kidney injury (2.3%), dehydration (1%), and pneumonitis (1%). Permanent discontinuation due to an adverse reaction occurred in 31% of patients; KEYTRUDA only (13%), axitinib only (13%), and the combination (8%); the most common were hepatotoxicity (13%), diarrhea/colitis (1.9%), acute kidney injury (1.6%), and cerebrovascular accident (1.2%). The most common adverse reactions (≥20%) were diarrhea (56%), fatigue/asthenia (52%), hypertension (48%), hepatotoxicity (39%), hypothyroidism (35%), decreased appetite (30%), palmar-plantar erythrodysesthesia (28%), nausea (28%), stomatitis/mucosal inflammation (27%), dysphonia (25%), rash (25%), cough (21%), and constipation (21%).
</p>
<p>
<b>Lactation</b>
</p>
<p>
Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the final dose.
</p>
<p>
<b>Pediatric Use </b>
</p>
<p>
There is limited experience in pediatric patients. In a trial, 40 pediatric patients (16 children aged 2 years to younger than 12 years and 24 adolescents aged 12 years to 18 years) with various cancers, including unapproved usages, were administered KEYTRUDA 2 mg/kg every 3 weeks. Patients received KEYTRUDA for a median of 3 doses (range 1–17 doses), with 34 patients (85%) receiving 2 doses or more. The safety profile in these pediatric patients was similar to that seen in adults; adverse reactions that occurred at a higher rate (≥15% difference) in these patients when compared to adults under 65 years of age were fatigue (45%), vomiting (38%), abdominal pain (28%), increased transaminases (28%), and hyponatremia (18%).
</p>
<p>
<b>Merck’s Focus on Cancer </b>
</p>
<p>
Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit <a href="http://www.merck.com/clinicaltrials" rel="nofollow" shape="rect">www.merck.com/clinicaltrials</a>.
</p>
<p>
<b>About Merck </b>
</p>
<p>
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world &#8211; including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit <a href="http://www.merck.com/" rel="nofollow" shape="rect">www.merck.com</a> and connect with us on <a href="https://twitter.com/Merck" rel="nofollow" shape="rect">Twitter</a>, <a href="https://www.facebook.com/MerckInvents/" rel="nofollow" shape="rect">Facebook</a>, <a href="https://www.instagram.com/merck/" rel="nofollow" shape="rect">Instagram</a>, <a href="https://www.youtube.com/user/Merck" rel="nofollow" shape="rect">YouTube</a> and <a href="https://www.linkedin.com/company/merck" rel="nofollow" shape="rect">LinkedIn</a>.
</p>
<p>
<b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA </b>
</p>
<p>
This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
</p>
<p>
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
</p>
<p>
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2018 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (<a href="https://www.sec.gov/" rel="nofollow" shape="rect">www.sec.gov</a><br />
<span class="bwuline">)</span>.
</p>
<p>
<b>Please see Prescribing Information for KEYTRUDA at <a href="http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf" rel="nofollow" shape="rect">http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf</a> and </b><br />
<b>Medication Guide for KEYTRUDA at <a href="http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf" rel="nofollow" shape="rect">http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf</a>.</b>
</p>
<p>
<img alt="" src="https://www.businesswire.com/images/spacer.gif" style="width:0;height:0"><br />
<span class="bwct31415"><br />
</span></p>
<p> Media: <br />Pamela Eisele <br />(267) 305-3558 </p>
<p>Ayn Wisler <br />(917) 691-6218 </p>
<p>Investors: <br />Peter Dannenbaum <br />(908) 740-1037 </p>
<p>Michael DeCarbo <br />(908) 740-1807 </p>
                        </div>
                        
                    </div>      

                                            <div id="sidebar-news" class="sidebar">
                            
                            <h2>Multimedia</h2>                                        <img src="https://s2.q4cdn.com/584635680/files/doc_events/2019/12/1/merck_logo.jpg" title="Merck Logo" style="max-width: 10rem;" />
                                        <br/>
                                        <a href="https://s2.q4cdn.com/584635680/files/doc_events/2019/12/1/merck_logo.jpg" target="_blank" title="Merck Logo">Merck Logo</a> <span class="text-descriptive">(21 KB)</span>
                                        <br/>
                                                            </div>
                                    </div><!-- .entry-content -->
                <div class="opt-in-communication-wrapper wrapper no-secondary-image" id="opt-in-communication-block-block_5e949a66cfcc9" aria-hidden="true">

                    <div class="opt-in-communication-block img-wrapper" style="position: relative;">
                        <picture class="opt-in-primary-img">
                            <source media="(max-width: 767px)" srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-.png?resize=321,196">
                            <source media="(min-width: 768px) and (max-width: 1279px)" srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-.png?resize=656,432">
                            <source media="(min-width: 1280px)" srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-.png?resize=516,596">
                            <img class="opt-in-primary-img lazyload" loading="lazy" src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/news-release-opt-in-image-.png?resize=516,596" alt="opt-in primary image"/>
                        </picture>
                    </div>

                    <div class="opt-in-left">
                        <div class="opt-in-left-content">
                                <h2 class="opt-in-title">Sign up for email alerts</h2>
                            <p class="opt-in-caption"></p>
                        </div>
                        <div class="opt-in-communication-block-iframe-holder">
                            <iframe id="opt-in-communication-block-block_5e949a66cfcc9-iFrame" src="https://merck2016rd.q4web.com/Email-Signup-New-Release/" style="width: 100%; overflow: hidden; height: 491px;" scrolling="no" frameborder="0"></iframe>
                            <script>
                                try {
                                    function iFrameResizerDefer(method) { if (typeof iFrameResize === "function") { method(); } else { setTimeout(function() { iFrameResizerDefer(method) }, 50); } }
                                    document.getElementById('opt-in-communication-block-block_5e949a66cfcc9-iFrame').onload = function() { iFrameResize({log:false}); };
                                } catch(ex) {
                                    console.log(ex);
                                } 
                            </script>

                        </div>
                    </div>

                </div>
                <p class="wrapper"><a href="https://www.merck.com/investor-relations/email-alerts/" class="btn secondary">Unsubscribe from email alerts</a></p>
                <footer class="entry-footer">
                                    </footer><!-- .entry-footer -->
            </article><!-- #post-745810 -->
		
        </main><!-- #main -->
	</div><!-- #primary -->
    
    <div class="related-content-container">
        <h4>Related links</h4>
        <div class="related-content-section">
            <div class="related-content-item">
                <a href="https://www.merck.com/media/company-statements/">
                    <div class="related-content-item-image-contianer">
                        <picture>
                            <source media="(max-width: 767px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png?resize=348,324">
                            <source media="(min-width: 768px) and (max-width: 1279px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png?resize=341,524">
                            <source media="(min-width: 1280px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png?resize=666,664">
                            <img  class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-1-.png" alt="related content image #1"/>
                        </picture>
                    </div>
                    <div class="related-content-content-container">
                        <p><strong>Company Statements</strong></p>
                        <p class="realted-content-excerpt">Read our latest company statements.</p>
                    </div>
                </a>
            </div>

            <div class="related-content-item">
                <a href="https://www.merck.com/media/media-library/">
                    <div class="related-content-item-image-contianer">
                        <picture>
                            <source media="(max-width: 767px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png?resize=348,324">
                            <source media="(min-width: 768px) and (max-width: 1279px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png?resize=341,524">
                            <source media="(min-width: 1280px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png?resize=666,664">
                            <img  class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-2.png" alt="related content image #2"/>
                        </picture>
                    </div>
                    <div class="related-content-content-container">
                        <p><strong>Media library</strong></p>
                        <p class="realted-content-excerpt">Access videos, logos, photos, and infographics.</p>
                    </div>
                </a>
            </div>

            <div class="related-content-item">
                <a href="https://www.merck.com/company-overview/">
                    <div class="related-content-item-image-contianer">
                        <picture>
                            <source media="(max-width: 767px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png?resize=348,324">
                            <source media="(min-width: 768px) and (max-width: 1279px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png?resize=341,524">
                            <source media="(min-width: 1280px)"
                                srcset="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png?resize=666,664">
                            <img  class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/stories-rl-3.png" alt="related content image #3"/>
                        </picture>
                    </div>
                    <div class="related-content-content-container">
                        <p><strong>About Merck</strong></p>
                        <p class="realted-content-excerpt">We are committed to providing leading innovations for today and the future that save and improve lives around the world.</p>
                    </div>
                </a>
            </div>
        </div>
    </div>

</div><!-- #content -->
<footer id="footerMain" class="footer">
    <div id="footerSocial">
        <div class="wrapper">
            <h3>Connect with us on social</h3>
            <div class="social-icons">
                                    <a href="https://twitter.com/Merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/twitter-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.facebook.com/MerckInvents" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/facebook-f-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.linkedin.com/company/merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/linkedin-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.instagram.com/merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/instagram-brands.svg" alt="social icon" />
                    </a>
                                    <a href="https://www.youtube.com/user/Merck" target="_blank">
                        <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/youtube-brands.svg" alt="social icon" />
                    </a>
                            </div>
        </div>
    </div>
    <div class="wrapper">
        <div id="footerPrograms">
                            <div class="column col-one">
                    <input type="checkbox" id="columnOne" class="checkbox-toggle">
                    <label for="columnOne" class="column-header">For patients and health care professionals</label>
                    <ul>
                        <li><a href="https://www.merckhelps.com/" target="_blank" rel="noopener">MerckHelps</a><br>
                            Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients</li>
                        <li><a href="https://www.merckaccessprogram.com/" target="_blank" rel="noopener">Merck Access Program</a><br>
                            Information about insurance coverage and financial assistance options for eligible patients</li>
                        <li><a href="https://www.merckclinicaltrials.com/" target="_blank" rel="noopener">Clinical trials</a><br>
                            Learn about our clinical trials and find available studies</li>
                        <li><a href="https://www.merckmanuals.com/" target="_blank" rel="noopener">Merck Manuals</a><br>
                            Medical information source covering thousands of topics in all fields of medicine</li>
                    </ul>
                </div>
            
                            <div class="column col-two">
                    <input type="checkbox" id="columnTwo" class="checkbox-toggle">
                    <label for="columnTwo" class="column-header">Environmental, Social &amp; Governance (ESG)</label>
                    <ul>
                                                    <li>
                                <a href="https://www.merck.com/company-overview/esg/" target="_blank" rel="noopener">Environmental, Social &amp; Governance (ESG) Report</a>
                                                                    <br />
                                    Reporting on our commitment to operating responsibly to benefit society                                                            </li>
                                                    <li>
                                <a href="https://www.merckformothers.com/" target="_blank" rel="noopener">Merck for Mothers</a>
                                                                    <br />
                                    An initiative to create a world where no woman has to die giving life                                                            </li>
                                            </ul>
                </div>
            
                            <div class="column col-three">
                    <input type="checkbox" id="columnThree" class="checkbox-toggle">
                    <label for="columnThree" class="column-header">About Merck</label>
                    <ul>
                        <li><a href="https://www.merck-animal-health.com/" target="_blank" rel="noopener">Merck Animal Health</a><br>
                            The global animal health business unit of Merck</li>
                        <li><a href="https://horizonblue.sapphiremrfhub.com/tocs/current/merck-co-inc" target="_blank" rel="noopener">Health Plan - Transparency in Coverage</a><br>
                            In compliance with the Consolidated Appropriations Act, learn more about our health plan's pricing information.</li>
                    </ul>
                </div>
                    </div>
        <div id="footerCopyrightLogos">
            <div id="footerCopyright">
                		<div class="menu-footer-menu-container"><ul id="menuFooter" class="footer-links"><li id="menu-item-674051" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-674051"><a href="https://www.merck.com/forward-looking-statement/">Forward-looking statement</a></li>
<li id="menu-item-137027" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-137027"><a target="_blank" rel="noopener" href="https://www.msdprivacy.com/us/en/cookie-privacy-policy.html">Cookie policy</a></li>
<li id="menu-item-763862" class="ot-sdk-show-settings menu-item menu-item-type-custom menu-item-object-custom menu-item-763862"><a href="#">Cookie Preferences</a></li>
<li id="menu-item-137025" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-137025"><a target="_blank" rel="noopener" href="https://www.msdprivacy.com/us/en/index.html">Privacy</a></li>
<li id="menu-item-137028" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-137028"><a target="_blank" rel="noopener" href="https://www.msdprivacy.com/us/en/transparency-and-privacy.html">Transparency disclosure</a></li>
<li id="menu-item-669400" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-669400"><a href="https://www.merck.com/terms-of-use/">Terms of use</a></li>
<li id="menu-item-3374425" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3374425"><a href="https://www.msdaccessibility.com/">Accessibility</a></li>
<li id="menu-item-669401" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-669401"><a href="https://www.merck.com/sitemap/">Sitemap</a></li>
</ul></div>                <small>
                    Copyright © 2022  <a href="https://www.myknot.club/">MyKnot</a>; Co., India and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.                h-merck-mco-theme/images/logo.jpeg"         </small>
            </div>
            <div id="footerLogos">
                                <a href="https://www.essentialaccessibility.com/merck/?utm_source=merckhomepage&amp;utm_medium=iconlarge&amp;utm_term=eachannelpage&amp;utm_content=header&amp;utm_campaign=merck" target="_blank" rel="noopener">
                    <img class="lazyload" loading="lazy" data-src="https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/images/accessibility.png" alt="Accessibility icon" />
                </a>
                <!-- Truste badges -->
                <a href="http://privacy.truste.com/privacy-seal/validation?rid=140649f5-9394-46e8-bfe5-b4ea8a8c600e" target="_blank" rel="noopener">
                    <img style="border: none" class="lazyload" loading="lazy" data-src="//privacy-policy.truste.com/privacy-seal/seal?rid=140649f5-9394-46e8-bfe5-b4ea8a8c600e" alt="View Privacy Shield Verification Status" />
                </a>
                <a href="http://privacy.truste.com/privacy-seal/validation?rid=11c1aa82-b7e7-4a2f-b02e-ba935e661720" target="_blank" rel="noopener">
                    <img style="border: none" class="lazyload" loading="lazy" data-src="//privacy-policy.truste.com/privacy-seal/seal?rid=11c1aa82-b7e7-4a2f-b02e-ba935e661720" alt="View APEC CBPR Privacy Certification Status" />
                </a>
            </div>
        </div>
    </div>
</footer><!-- #footerMain -->
</div><!-- #page -->
<div id="fowardGuidanceModel" class="popup" style="display: none;">
    <div class="popup-wrapper">
        <div class="popup-content foward-guide-modal-content">

            <h3>Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA</h3>

            <div class="forward-guidance-content">
                <p>This news release of Merck &amp; Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.<br><br>

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.<br><br>

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2021 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).<br><br>

<b>No Duty to Update</b><br>

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

</p>            </div>

            <div class="btn-container text-center">
                <a href="https://www.merck.com/" class="btn tertiary">Decline</a>
                <a href="javascript:void()" class="btn tertiary negative" title="" onclick="sessionStorage.setItem('guidance-accepted', JSON.stringify(true)); document.getElementById('fowardGuidanceModel').style.display = 'none';">Accept</a>
            </div>

        </div>
    </div>
</div>
<link rel='stylesheet' id='related-content-styles-css'  href='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/css/related-content-section.min.css?ver=5.9.4' media='all' />
<script defer="defer" src='https://www.merck.com/wp-content/plugins/mhh-corporateberg/opt-in-communication-block/js/iframeResizer.min.js?ver=5.9.4' id='iframe-resize-js-js'></script>
<script defer="defer" src='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/js/plugins.min.js?ver=20190301' id='Mco-plugins-js'></script>
<script defer="defer" src='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/js/scripts.min.js?ver=20190301' id='Mco-scripts-js'></script>
<script defer="defer" src='https://www.merck.com/wp-content/themes/mhh-merck-mco-theme/js/search_suggestions.min.js?ver=1664904139' id='search_suggestion-js'></script>
<div id="externalLinkModal" class="popup" style="display: none;">
    <div class="popup-wrapper">
        <div class="popup-content foward-guide-modal-content">

            <h3 id="externalLinkModalTitle">You are leaving Merck.com</h3>

            <div class="forward-guidance-content">
                <p id="externalLinkModalMessage" style="max-width: 31.25rem;"></p>
            </div>
            
            <div class="btn-container text-center">
                <button class="btn tertiary" id="externalLinkCancelBtn" title="" onclick="document.getElementById('externalLinkModal').style.display = 'none';">Cancel</button>
                <a href="#" target="_blank" class="btn tertiary negative" id="externalLinkModalBtn">Continue</a>
            </div>
        
        </div>
    </div>
</div>

<script type="text/javascript">
    let whitelist_domains =  ".local,merck-go-vip,merck-develop.go-vip.co/merck,merck-preprod.go-vip.co/merck,vip-msd.com/merck,merck.com,q4cdn.com,cloudfront.net,wpvip-safety-data-sheets.s3.amazonaws.com,google.com/calendar,outlook.live.com/calendar,calendar.yahoo.com,merckhelps.com,merckaccessprogram.com,merckmanuals.com,merckconnect.com,merckclinicaltrials.com,merck-animal-health.com,merckformothers.com,mrknewsroom.com,facebook.com,twitter.com,linkedin.com,mailto:,javascript:,tel:";
    let whitelist_domains_array = whitelist_domains.split(',');
    whitelist_domains_array.unshift(document.location.hostname);
        // External Links
    try {
        let links = Array.from(document.links);
        for (let i = 0; i < links.length; i++) {
            let link = links[i];
            if (!shouldWhitelistDomain(link.href)) {
                link.addEventListener("click", function (e) {
                    e.preventDefault();
                    let modal_data = getLinkContent(link.href);
                    document.getElementById('externalLinkModalTitle').textContent = modal_data.title;
                    document.getElementById('externalLinkModalMessage').textContent = modal_data.message;
                    document.getElementById('externalLinkModalBtn').href = this.href;
                    document.getElementById('externalLinkModalBtn').setAttribute('onclick', 'document.getElementById(\'externalLinkModal\').style.display = "none";');
                    document.getElementById('externalLinkModal').style.display = document.getElementById('externalLinkModal').style.display === 'none' ? 'block' : 'none';
                    
                    if (modal_data.cancelBtnText){
                        document.getElementById('externalLinkCancelBtn').textContent = modal_data.cancelBtnText;

                    }
                    if (modal_data.continueBtnText){
                        document.getElementById('externalLinkModalBtn').textContent = modal_data.continueBtnText;
                    }
                });
            }
        }
    } catch(ex) {
        console.log(ex);
    }

    function getLinkContent(link) {
        try {
            let title = htmlDecode("You are leaving Merck.com");
            let message = htmlDecode("The link you have selected will direct you to a site outside of www.merck.com. We are Merck &amp; Co. Inc., Rahway, NJ, USA known as MSD outside the United States and Canada. ");
            let cancelBtnText = htmlDecode("");
            let continueBtnText = htmlDecode("");
                        data = {
                title: title,
                message: message,
                cancelBtnText: cancelBtnText,
                continueBtnText: continueBtnText
            }
            return data;
        }
        catch(ex) {
            console.log(ex);
        }
    }

    function htmlDecode(input){
        if (input === '') return '';
        var e = document.createElement('div');
        e.innerHTML = input;
        return e.childNodes[0].nodeValue;
    }

    function shouldWhitelistDomain(link){
        return whitelist_domains_array.some(domain => new RegExp(domain).test(link));
    }
</script>
<div id="ukUserModal" class="popup" style="display: none;">
    <div class="popup-wrapper">
        <div class="popup-content foward-guide-modal-content">

            <h3>Welcome to Merck.com</h3>

            <div class="forward-guidance-content">
                <p style="max-width: 31.25rem;">By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.</p>
            </div>

            <div class="btn-container text-center">
                <a target="_blank" class="btn tertiary negative" id="externalLinkModalBtn" onclick="AcceptUKMessage();">Continue</a>
            </div>

        </div>
    </div>
</div>

<script type="text/javascript">
    function AcceptUKMessage() {
        try {
            let accepted = {
                expire: new Date(new Date().getTime() + 60 * 60 * 24 * 1000)
            };
            sessionStorage.setItem('uk-messaging', JSON.stringify(accepted));
            document.getElementById('ukUserModal').style.display = 'none';
        } catch (ex) {
            console.log(ex);
        }
    }
</script>

<script>console.log("US");</script><script>
		utag_data.page_datepublished = "2019-12-20 06:45:00";
	utag_data.page_datemodified = "2022-10-04 00:05:43";
	dataLayer.push(utag_data);
</script>

	<!-- OneTrust Cookies Consent Notice start -->
	<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js"  type="text/javascript" charset="UTF-8" data-domain-script="fd658a96-8c4a-4c03-973e-fd83f98fa618"></script>
	<script type="text/javascript">
		function OptanonWrapper() { }
	</script>
	<!-- OneTrust Cookies Consent Notice end -->
	<script type="text/javascript">
                        /*
* FileSaver.js
* A saveAs() FileSaver implementation.
*
* By Eli Grey, http://eligrey.com
*
* License : https://github.com/eligrey/FileSaver.js/blob/master/LICENSE.md (MIT)
* source  : http://purl.eligrey.com/github/FileSaver.js
*/

// The one and only way of getting global scope in all environments
// https://stackoverflow.com/q/3277182/1008999
var _global = typeof window === 'object' && window.window === window
  ? window : typeof self === 'object' && self.self === self
  ? self : typeof global === 'object' && global.global === global
  ? global
  : this

function bom (blob, opts) {
  if (typeof opts === 'undefined') opts = { autoBom: false }
  else if (typeof opts !== 'object') {
    console.warn('Deprecated: Expected third argument to be a object')
    opts = { autoBom: !opts }
  }

  // prepend BOM for UTF-8 XML and text/* types (including HTML)
  // note: your browser will automatically convert UTF-16 U+FEFF to EF BB BF
  if (opts.autoBom && /^\s*(?:text\/\S*|application\/xml|\S*\/\S*\+xml)\s*;.*charset\s*=\s*utf-8/i.test(blob.type)) {
    return new Blob([String.fromCharCode(0xFEFF), blob], { type: blob.type })
  }
  return blob
}

function download (url, name, opts) {
  var xhr = new XMLHttpRequest()
  xhr.open('https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/GET', url)
  xhr.responseType = 'blob'
  xhr.onload = function () {
    saveAs(xhr.response, name, opts)
  }
  xhr.onerror = function () {
    console.error('could not download file')
  }
  xhr.send()
}

function corsEnabled (url) {
  var xhr = new XMLHttpRequest()
  // use sync to avoid popup blocker
  xhr.open('https://www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/HEAD', url, false)
  try {
    xhr.send()
  } catch (e) {}
  return xhr.status >= 200 && xhr.status <= 299
}

// `a.click()` doesn't work for all browsers (#465)
function click (node) {
  try {
    node.dispatchEvent(new MouseEvent('click'))
  } catch (e) {
    var evt = document.createEvent('MouseEvents')
    evt.initMouseEvent('click', true, true, window, 0, 0, 0, 80,
                          20, false, false, false, false, 0, null)
    node.dispatchEvent(evt)
  }
}

// Detect WebView inside a native macOS app by ruling out all browsers
// We just need to check for 'Safari' because all other browsers (besides Firefox) include that too
// https://www.whatismybrowser.com/guides/the-latest-user-agent/macos
var isMacOSWebView = /Macintosh/.test(navigator.userAgent) && /AppleWebKit/.test(navigator.userAgent) && !/Safari/.test(navigator.userAgent)

var saveAs = _global.saveAs || (
  // probably in some web worker
  (typeof window !== 'object' || window !== _global)
    ? function saveAs () { /* noop */ }

  // Use download attribute first if possible (#193 Lumia mobile) unless this is a macOS WebView
  : ('download' in HTMLAnchorElement.prototype && !isMacOSWebView)
  ? function saveAs (blob, name, opts) {
    var URL = _global.URL || _global.webkitURL
    var a = document.createElement('a')
    name = name || blob.name || 'download'

    a.download = name
    a.rel = 'noopener' // tabnabbing

    // TODO: detect chrome extensions & packaged apps
    // a.target = '_blank'

    if (typeof blob === 'string') {
      // Support regular links
      a.href = blob
      if (a.origin !== location.origin) {
        corsEnabled(a.href)
          ? download(blob, name, opts)
          : click(a, a.target = '_blank')
      } else {
        click(a)
      }
    } else {
      // Support blobs
      a.href = URL.createObjectURL(blob)
      setTimeout(function () { URL.revokeObjectURL(a.href) }, 4E4) // 40s
      setTimeout(function () { click(a) }, 0)
    }
  }

  // Use msSaveOrOpenBlob as a second approach
  : 'msSaveOrOpenBlob' in navigator
  ? function saveAs (blob, name, opts) {
    name = name || blob.name || 'download'

    if (typeof blob === 'string') {
      if (corsEnabled(blob)) {
        download(blob, name, opts)
      } else {
        var a = document.createElement('a')
        a.href = blob
        a.target = '_blank'
        setTimeout(function () { click(a) })
      }
    } else {
      navigator.msSaveOrOpenBlob(bom(blob, opts), name)
    }
  }

  // Fallback to using FileReader and a popup
  : function saveAs (blob, name, opts, popup) {
    // Open a popup immediately do go around popup blocker
    // Mostly only available on user interaction and the fileReader is async so...
    popup = popup || open('', '_blank')
    if (popup) {
      popup.document.title =
      popup.document.body.innerText = 'downloading...'
    }

    if (typeof blob === 'string') return download(blob, name, opts)

    var force = blob.type === 'application/octet-stream'
    var isSafari = /constructor/i.test(_global.HTMLElement) || _global.safari
    var isChromeIOS = /CriOS\/[\d]+/.test(navigator.userAgent)

    if ((isChromeIOS || (force && isSafari) || isMacOSWebView) && typeof FileReader !== 'undefined') {
      // Safari doesn't allow downloading of blob URLs
      var reader = new FileReader()
      reader.onloadend = function () {
        var url = reader.result
        url = isChromeIOS ? url : url.replace(/^data:[^;]*;/, 'data:attachment/file;')
        if (popup) popup.location.href = url
        else location = url
        popup = null // reverse-tabnabbing #460
      }
      reader.readAsDataURL(blob)
    } else {
      var URL = _global.URL || _global.webkitURL
      var url = URL.createObjectURL(blob)
      if (popup) popup.location = url
      else location.href = url
      popup = null // reverse-tabnabbing #460
      setTimeout(function () { URL.revokeObjectURL(url) }, 4E4) // 40s
    }
  }
)

_global.saveAs = saveAs.saveAs = saveAs

if (typeof module !== 'undefined') {
  module.exports = saveAs;
}

/*! ics.js Wed Sept 14 2017 */
var ics=function(e,t){"use strict";{if(!(navigator.userAgent.indexOf("MSIE")>-1&&-1==navigator.userAgent.indexOf("MSIE 10"))){void 0===e&&(e="default"),void 0===t&&(t="Calendar");var r=-1!==navigator.appVersion.indexOf("Win")?"\r\n":"\n",n=[],i=["BEGIN:VCALENDAR","PRODID:"+t,"VERSION:2.0"].join(r),o=r+"END:VCALENDAR",a=["SU","MO","TU","WE","TH","FR","SA"];return{events:function(){return n},calendar:function(){return i+r+n.join(r)+o},addEvent:function(t,i,o,l,u,s){if(void 0===t||void 0===i||void 0===o||void 0===l||void 0===u)return!1;if(s&&!s.rrule){if("YEARLY"!==s.freq&&"MONTHLY"!==s.freq&&"WEEKLY"!==s.freq&&"DAILY"!==s.freq)throw"Recurrence rrule frequency must be provided and be one of the following: 'YEARLY', 'MONTHLY', 'WEEKLY', or 'DAILY'";if(s.until&&isNaN(Date.parse(s.until)))throw"Recurrence rrule 'until' must be a valid date string";if(s.interval&&isNaN(parseInt(s.interval)))throw"Recurrence rrule 'interval' must be an integer";if(s.count&&isNaN(parseInt(s.count)))throw"Recurrence rrule 'count' must be an integer";if(void 0!==s.byday){if("[object Array]"!==Object.prototype.toString.call(s.byday))throw"Recurrence rrule 'byday' must be an array";if(s.byday.length>7)throw"Recurrence rrule 'byday' array must not be longer than the 7 days in a week";s.byday=s.byday.filter(function(e,t){return s.byday.indexOf(e)==t});for(var c in s.byday)if(a.indexOf(s.byday[c])<0)throw"Recurrence rrule 'byday' values must include only the following: 'SU', 'MO', 'TU', 'WE', 'TH', 'FR', 'SA'"}}var g=new Date(l),d=new Date(u),f=new Date,S=("0000"+g.getFullYear().toString()).slice(-4),E=("00"+(g.getMonth()+1).toString()).slice(-2),v=("00"+g.getDate().toString()).slice(-2),y=("00"+g.getHours().toString()).slice(-2),A=("00"+g.getMinutes().toString()).slice(-2),T=("00"+g.getSeconds().toString()).slice(-2),b=("0000"+d.getFullYear().toString()).slice(-4),D=("00"+(d.getMonth()+1).toString()).slice(-2),N=("00"+d.getDate().toString()).slice(-2),h=("00"+d.getHours().toString()).slice(-2),I=("00"+d.getMinutes().toString()).slice(-2),R=("00"+d.getMinutes().toString()).slice(-2),M=("0000"+f.getFullYear().toString()).slice(-4),w=("00"+(f.getMonth()+1).toString()).slice(-2),L=("00"+f.getDate().toString()).slice(-2),O=("00"+f.getHours().toString()).slice(-2),p=("00"+f.getMinutes().toString()).slice(-2),Y=("00"+f.getMinutes().toString()).slice(-2),U="",V="";y+A+T+h+I+R!=0&&(U="T"+y+A+T,V="T"+h+I+R);var B,C=S+E+v+U,j=b+D+N+V,m=M+w+L+("T"+O+p+Y);if(s)if(s.rrule)B=s.rrule;else{if(B="rrule:FREQ="+s.freq,s.until){var x=new Date(Date.parse(s.until)).toISOString();B+=";UNTIL="+x.substring(0,x.length-13).replace(/[-]/g,"")+"000000Z"}s.interval&&(B+=";INTERVAL="+s.interval),s.count&&(B+=";COUNT="+s.count),s.byday&&s.byday.length>0&&(B+=";BYDAY="+s.byday.join(","))}(new Date).toISOString();var H=["BEGIN:VEVENT","UID:"+n.length+"@"+e,"CLASS:PUBLIC","DESCRIPTION:"+i,"DTSTAMP;VALUE=DATE-TIME:"+m,"DTSTART;VALUE=DATE-TIME:"+C,"DTEND;VALUE=DATE-TIME:"+j,"LOCATION:"+o,"SUMMARY;LANGUAGE=en-us:"+t,"TRANSP:TRANSPARENT","END:VEVENT"];return B&&H.splice(4,0,B),H=H.join(r),n.push(H),H},download:function(e,t){if(n.length<1)return!1;t=void 0!==t?t:".ics",e=void 0!==e?e:"calendar";var a,l=i+r+n.join(r)+o;if(-1===navigator.userAgent.indexOf("MSIE 10"))a=new Blob([l]);else{var u=new BlobBuilder;u.append(l),a=u.getBlob("text/x-vCalendar;charset="+document.characterSet)}return saveAs(a,e+t),l},build:function(){return!(n.length<1)&&i+r+n.join(r)+o}}}console.log("Unsupported Browser")}};


function GenerateICS(title, description, start, end) {
    let cal = new ics();
    cal.addEvent(decodeURIComponent(title), decodeURIComponent(description), "", start, end);
    cal.download(decodeURIComponent(title));
}
</script><script>
    /* https://stackoverflow.com/a/26633844/3019650 */
    if (!window.CSS || !CSS.supports('color', 'var(--fake-var)')) {
        (function(a, b, c, d) {
            a = 'https://cdn.jsdelivr.net/npm/css-vars-ponyfill@2';
            b = document;
            c = 'script';
            d = b.createElement(c);
            d.src = a;
            d.type = 'text/java' + c;
            d.async = true;
            a = b.getElementsByTagName(c)[0];
            a.parentNode.insertBefore(d, a);
        })();

        function deferCssVars(method) {
            if (typeof cssVars === "function") {
                method();
            } else {
                setTimeout(function() {
                    deferCssVars(method)
                }, 50);
            }
        }
        deferCssVars(function() {
            cssVars()
        });
    }
</script>
</body>


<!-- Mirrored from www.merck.com/news/mercks-keytruda-pembrolizumab-approved-in-japan-for-three-new-first-line-indications-across-advanced-renal-cell-carcinoma-rcc-and-recurrent-or-distant-metastatic-head-and-neck-cance/ by HTTrack Website Copier/3.x [XR&CO'2014], Tue, 04 Oct 2022 17:41:10 GMT -->
</html>
